COUR Pharmaceutical Development

Takeda acquires TAK-101 license from COUR in $420m deal
Pharmaceutical Business Review
Wed, 10/23/19 - 10:16 am
Takeda
COUR Pharmaceutical Development
CNP-101
TAK-101
celiac disease